What question did this study set out to answer?

To evaluate the justification and evidence supporting anti-malarial policy changes in Malawi.

May 25, 2026Open Access

Malaria research and its influence on anti-malarial drug policy in Malawi: a case study

Key Points

To evaluate the justification and evidence supporting anti-malarial policy changes in Malawi.
Examined historical data on anti-malarial drug changes from chloroquine to sulfadoxine-pyrimethamine and then to lumefantrine-artemether
Analyzed the implications of these changes on drug resistance and treatment efficacy.
The 1993 policy change raised concerns about timely implementation and potential resistance development to sulfadoxine-pyrimethamine.
Evidence suggests changing drug policies may have influenced the resistance patterns of Plasmodium falciparum in Malawi.

Abstract

In 1993, Malawi changed its first-line anti-malarial treatment for uncomplicated malaria from chloroquine to sulfadoxine-pyrimethamine (SP), and in 2007, it changed from SP to lumefantrine-artemether. The change in 1993 raised concerns about whether it had occurred timely and whether it had potentially led to early development of Plasmodium falciparum resistance to SP. This case study examined evidence from Malawi in order to assess if the policy changes were justifiable and supported by evidence.

Read Full Paperexternally

Demander à l'IA

Bookmark

View Full Paper

Cite This Study

Human Sciences Research Council (Sat,) studied this question.

synapsesocial.com/papers/6a13e7cf0e02ee3982d3266a https://doi.org/https://doi.org/10.14749/32384724

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

Demander à l'IA

Bookmark

View Full Paper